During the corresponding time, Emmaus Life Sciences Inc recorded a revenue increase by 24.62 % year on year, While revenue at the Emmaus Life Sciences Inc 's corporate clients
Emmaus Life Sciences Inc's Comment on Sales, Marketing and Customers
The company sells Endari® to specialty distributors and specialty pharmacies, which then resell the product to pharmacies, hospitals, and other customers. Four distributors accounted for approximately 62% of Endari® sales in the year ended December 31, 2025. The U.S. pharmaceutical distribution market is undergoing consolidation, leading to increased competitive and pricing pressures. Endari® is a prescription-grade L-glutamine oral powder treatment for sickle cell anemia (SCD) and sickle ß0-thalassemia. SCD affects 20 to 25 million people worldwide, primarily in regions including sub-Saharan Africa, South America, the Caribbean, Central America, the Middle East, India, and Mediterranean countries such as Turkey, Greece, and Italy. Many potential customers are located in markets with underdeveloped healthcare systems and lower health insurance coverage. The U.S. market exclusivity for Endari® expired in July 2024, and there is limited or no market exclusivity in the Middle East and North Africa (MENA) region, which may impact sales and competition.
Emmaus Life Sciences Inc’s Comment on Sales, Marketing and Customers
The company sells Endari® to specialty distributors and specialty pharmacies, which then resell the product to pharmacies, hospitals, and other customers. Four distributors accounted for approximately 62% of Endari® sales in the year ended December 31, 2025. The U.S. pharmaceutical distribution market is undergoing consolidation, leading to increased competitive and pricing pressures. Endari® is a prescription-grade L-glutamine oral powder treatment for sickle cell anemia (SCD) and sickle ß0-thalassemia. SCD affects 20 to 25 million people worldwide, primarily in regions including sub-Saharan Africa, South America, the Caribbean, Central America, the Middle East, India, and Mediterranean countries such as Turkey, Greece, and Italy. Many potential customers are located in markets with underdeveloped healthcare systems and lower health insurance coverage. The U.S. market exclusivity for Endari® expired in July 2024, and there is limited or no market exclusivity in the Middle East and North Africa (MENA) region, which may impact sales and competition.
Sources:
Emmaus Life Sciences Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Emmaus Life Sciences Inc’s corporate clients.
For your research, we’ve provided 9 tables on Emmaus Life Sciences Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
